Employees: 137
Size vVARDIS (VVVV) is a United States Health Care company (Medical Specialties) with a market value of $594M, the 2557th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.47 on 18 Nov 2026.
Growth Revenue grew 148.5% over the last twelve months (peer median +14.4%); the operating margin is -71.6% (peer median 8.5%).
Valuation It trades at 14.3× enterprise value to sales against a peer median of 3.8× (2nd most expensive of 20).
Capital Return on invested capital runs 114.0 points below its cost of capital (9.1% WACC).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | $49.7M | $30.2M | $12.2M |
| Revenue growth | — | +148% | — |
| Gross profit | $38.0M | $18.7M | $3.91M |
| EBITDA | -$31.1M | -$38.1M | -$27.1M |
| Net income | -$52.2M | -$56.5M | -$34.7M |
| Free cash flow | -$10.6M | -$17.1M | -$23.8M |
| Capital expenditure | $2.56M | $2.81M | $325,000 |
| Total debt | n/a | $107M | $73.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VVVV | Peer median | Rank in peer set |
|---|---|---|---|
| Revenue growth (TTM) | +148.5% | +14.4% | 2nd highest of 20 |
| Operating margin | -71.6% | 8.5% | 3rd lowest of 20 |
| EV / Sales | 14.3× | 3.8× | 2nd most expensive of 20 |
| ROIC minus cost of capital | -114.0 pp | +1.7 pp | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | 14.3× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 1.5× | 8.4% | +12.0% |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 3.7× | 0.4% | +27.8% |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | 6.4× | n/a | n/a |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 7.1× | -1.2% | +14.5% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 5.4× | n/a | n/a |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 3.8× | 35.3% | +6.7% |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | 18.3× | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 6.3× | 35.9% | +35.2% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 3.3× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | 6.7× | n/a | n/a |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $618M | -27% | -13% | 31% | 2.1× | -8.5% | +2.2% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 1.6× | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | 5.9× | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | 8.3× | -2.6% | +18.8% |
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 2.1× | -11.5% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | 5.5× | 15.0% | -19.8% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 2.6× | 10.2% | +6.5% |
| QuidelOrtho QDEL | United States | $657M | -20% | -5% | -2% | 1.4× | n/a | n/a |
| Synektik SNT.WA | Poland | $662M | +10% | +32% | 24% | 2.9× | 0.2% | +47.5% |